跳至主要内容
临床试验/CTRI/2024/06/068821
CTRI/2024/06/068821尚未招募2 期

A Single-blind Standard Controlled Randomized clinical trial of Unani formulation in the management of Kalaf (Melasma).

DEPARTMENT OF AMRAZ E JILD WA ZOHRAWIYA1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年7月15日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
80
试验地点
1
主要终点
Modified Melasma Area and Severity Index score (mMASI score).

研究概览

简要总结

The objective of the study is to evaluate the efficacy and safety of  Rewand Chini (Rheum emodi) in paste form for local application in the management of Kalaf*(Melasma)*

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 50.00 Year(s)(—)
性别
All

入选标准

  • Age- 18 years and above.
  • Both male and female patients.
  • All skin types (Fitzpatrick I to VI).
  • Patients who signed the written consent form.
  • Epidermal and mixed pattern of melasma.

排除标准

  • Patients below 18 years.
  • Patient with systemic disease eg: DM, Malignancy, Thyroid dysfunction, CKD, and TB (as per history and clinical examination).
  • History of hypersensitivity reaction to drugs.
  • Patients who were not willing to sign the consent form or remain absent during the study.
  • Pregnant and Lactating mothers.
  • Women who are on OCPs (progesterone).

结局指标

主要结局

Modified Melasma Area and Severity Index score (mMASI score).

时间窗: 15th, 30th, 45th day

Melasma Quality of Life scale (MelasQoL)

时间窗: 15th, 30th, 45th day

Photographs (without using filters)

时间窗: 15th, 30th, 45th day

次要结局

  • Fairness, Glow, and Shining(15th, 30th, 45th day)

研究者

发起方
DEPARTMENT OF AMRAZ E JILD WA ZOHRAWIYA
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Safiya Naiyar

Ajmal Khan Tibbia College

研究点 (1)

Loading locations...

相似试验